-
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedF Zannad, JP Ferreira, SJ Pocock et al. -
Dapagliflozin for treating chronic heart failure with reduced ejection fractionNational Institue for Health and Care Excellence
-
INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection FractionA Samman-Tahhan, JS Hedley, AA. McCue et al.
-
Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art ReviewM.G.D Buono, R Arena, BA Borlaug et al.
-
Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart FailureJA Chirinos, L Zhao, Y Jia et al.
-
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 StudyKosiborod M, Lam CSP, CVD-REAL Investigators and Study Group.
-
The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and TreatmentBA Borlaug, YNV Reddy.
-
The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) StudyIbrahim NE, Januzzi JL Jr.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
